Tackling reproducibility in academic preclinical drug discovery

被引：43

作者：

Frye, Stephen V. ^{[1
]}

Arkin, Michelle R. ^{[2
]}

Arrowsmith, Cheryl H. ^{[3
]}

Conn, P. Jeffrey ^{[4
]}

Glicksman, Marcie A. ^{[5
]}

Hull-Ryde, Emily A. ^{[1
]}

Slusher, Barbara S. ^{[6
]}

机构：

[1] Univ N Carolina, Eshelman Sch Pharm, Ctr Integrat Chem Biol & Drug Discovery, Chapel Hill, NC 27599 USA

[2] Univ Calif San Francisco, Sch Pharm, Small Mol Discovery Ctr, San Francisco, CA 94143 USA

[3] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada

[4] Vanderbilt Univ, Vanderbilt Ctr Neurosci Drug Discovery, Dept Pharmacol, Nashville, TN 37232 USA

[5] ORIG3N, Boston, MA 02210 USA

[6] Johns Hopkins Sch Med, Johns Hopkins Drug Discovery, Baltimore, MD 21205 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2015年 / 14卷 / 11期

关键词：

D O I：

10.1038/nrd4737

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.

引用

下载

页码：733 / 734

页数：2

共 50 条

[31] Personalised drug discovery: An academic experience
Andre, F.
Arnedos, M.
Delaloge, S.
Bonnefoi, H.
Bachelot, T.
Soria, J. C.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S51 - S51
[32] Drug Discovery in Academic Settings INTRODUCTION
Iyengar, Ravi
MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (04): : 325 - 326
[33] The Alabama Drug Discovery Alliance: A Collaborative Partnership to Facilitate Academic Drug Discovery
Everts, Maaike
Knight, W. Blaine
Harris, David R.
Secrist, John A., III
Whitley, Richard J.
PHARMACEUTICAL RESEARCH, 2011, 28 (07) : 1454 - 1459
[34] The Alabama Drug Discovery Alliance: A Collaborative Partnership to Facilitate Academic Drug Discovery
Maaike Everts
W. Blaine Knight
David R. Harris
John A. Secrist
Richard J. Whitley
Pharmaceutical Research, 2011, 28 : 1454 - 1459
[35] Managing risks in drug discovery: reproducibility of published findings
Kannt, Aimo
Wieland, Thomas
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (04) : 353 - 360
[36] Managing risks in drug discovery: reproducibility of published findings
Aimo Kannt
Thomas Wieland
Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389 : 353 - 360
[37] NIMH Preclinical/Clinical Therapeutics Research Meeting - Preclinical Drug Discovery session
Douglas, Steven D.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2007, 2 (01) : 5 - 7
[38] NIMH Preclinical/Clinical Therapeutics Research Meeting—Preclinical Drug Discovery Session
Steven D. Douglas
Journal of Neuroimmune Pharmacology, 2007, 2 : 5 - 7
[39] Preclinical experimental models of drug metabolism and disposition in drug discovery and development
Zhang, Donglu
Luo, Gang
Ding, Xinxin
Lu, Chuang
ACTA PHARMACEUTICA SINICA B, 2012, 2 (06) : 549 - 561
[40] Approaches to seizure risk assessment in preclinical drug discovery
Easter, Alison
Bell, M. Elizabeth
Damewood, James R., Jr.
Redfern, William S.
Valentin, Jean-Pierre
Winter, Matthew J.
Fonck, Carlos
Bialecki, Russell A.
DRUG DISCOVERY TODAY, 2009, 14 (17-18) : 876 - 884

← 1 2 3 4 5 →